Cotellic (cobimetinib) could be a cancer drugs that interferes with the expansion and unfold of cancer cells within thebody.
Cotellic is employed to treat an explicit sort of pathological process skin cancer (skin cancer) that has unfold todifferent elements of the body and can’t be removed with surgery.
Cotellic is typically given along with another drugs referred to as vemurafenib (Zelboraf).
Cotellic is employed as long as your tumour features a specific cistron that your doctor can check for.
Submit your review
Get emergency medical help if you have signs of an allergic reaction to Cotellic: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using Cotellic and call your doctor at once if you have:
vision changes, partial vision loss, seeing halos around lights;
unexplained muscle pain, tenderness, or weakness (especially if you also have fever and dark colored urine);
easy bruising or bleeding (nosebleeds, bleeding gums);
signs of bleeding inside the body - weakness, dizziness, headache, red or pink urine, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
signs of a heart problem - cough, wheezing, shortness of breath (even with mild exertion), chest pain, fast heartbeats, swelling in your feet or ankles;
low levels of sodium in the body - headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady;
liver problems - nausea, upper stomach pain, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
severe skin reaction - skin pain, itching, redness, bumps or pimples, thickened or wrinkled skin, skin rash that spreads and causes blistering and peeling.
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common Cotellic side effects may include:
nausea, vomiting, diarrhea;
sunburn or increased sensitivity to sunlight;
low sodium levels; or
abnormal laboratory tests.
60 mg orally once a day for first 21 days of each 28-day cycle Duration of therapy: Until disease progression or unacceptable toxicity Comments: The presence of BRAF V600E or V600K mutation in tumor specimens should be confirmed with an FDA-approved test prior to treatment initiation; information on FDA-approved tests available at http://www.fda.gov/CompanionDiagnostics. Use: In combination with vemurafenib, indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.